Acarbose

Generic Pharmaceuticals Global Markets Report 2022: Focus on CNS; Cardiovascular; Dermatology; Genitourinary/Hormonal; Respiratory; Rheumatology; Diabetes; Oncology - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022
Health, Pharmaceutical, Code, Time, CNS, US Foods, Canadian International Council, FDA, Patent, Rheumatology, Pharmacist, GSK, The One, Safety, World, Acarbose, Death, Technology, Method, Dermatology, WHO, CVS, Taste, Pharmacy, Conditional sentence, Aztreonam, Research, Distribution, CGMP, Tablet, Marketing, Advertising, HEALTH, 3D, World Health Organization, Pharmacology, Parkinson's disease, Incidence, Food, Acebutolol, Patient, CFR, Metformin, Awareness, Food and Drug Administration, Metoprolol, Diabetes, Biosimilar, Pharmaceutical industry, Generic drug, Medical device, Dietary supplement, GlaxoSmithKline

Generic drugs are manufactured after the expiration of the exclusive rights or patent of the branded drugs.

Key Points: 
  • Generic drugs are manufactured after the expiration of the exclusive rights or patent of the branded drugs.
  • For example, some of the generic drugs in the generic pharmaceuticals market include metformin, metoprolol, acarbose, acebutolol, aztreonam and many more.
  • The main types of generic pharmaceuticals are biosimilar; simple generic and super generic.
  • The low cost and same chemical composition and strength of generic drugs make a patient buy generic drugs instead of branded drugs.

Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

Retrieved on: 
Wednesday, December 22, 2021
U.S. Securities and Exchange Commission, Novartis, Drug development, Medicine, Transplant, Anesthesiology, Kidney, Acarbose, Patient, Immunity, Private Securities Litigation Reform Act, Coronavirus, Internal medicine, Infection, CEO, Medical Affairs Bureau, CMO, International development, Degenerative disease, Diabetes, NASDAQ, University, Senior, Forward-looking statement, Health, COVID-19, Autoimmunity, Faculty, Artemether/lumefantrine, Allergy, Yale school, Zai, Ciprofloxacin, SAN, Â, Risk, GLOBE, Pharmaceutical industry, Telbivudine, Daptomycin, Neuroscience

Dr. Reinhart has been with the company since inception, first as an advisor and since 2017, as Chief Medical Officer responsible for the autoimmune and infectious diseases portfolio.

Key Points: 
  • Dr. Reinhart has been with the company since inception, first as an advisor and since 2017, as Chief Medical Officer responsible for the autoimmune and infectious diseases portfolio.
  • Harald has played a pivotal role in building Zai Labs broad and deep pipeline in autoimmune, infectious diseases and neuroscience, said Dr. Samantha Du, Founder, Chairperson and CEO at Zai Lab.
  • This promotion not only recognizes Haralds tremendous contributions but will also empower him to further build a leading clinical team across these therapeutic areas.
  • He completed his medical and subspecialty training in the U.S. with board-certifications in internal medicine and infectious diseases.

Global $64.95 Bn Antidiabetic Drug Markets, 2021-2026 by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 25, 2021
Diabetes, Pharmaceutical, Health, CAGR, Acarbose, Growth, Geography, Diabetes, Pioglitazone, Research, Health, Sitagliptin, Person, Prevalence, Ageing, Time, National Children's Mental Health Awareness Week, Investment, Adult, Metformin, USD, Obesity, Pharmaceutical industry

The Global Antidiabetic Drug Market is estimated to be USD 38.20 Bn in 2021 and is expected to reach USD 64.95 Bn by 2026, growing at a CAGR of 11.2%.

Key Points: 
  • The Global Antidiabetic Drug Market is estimated to be USD 38.20 Bn in 2021 and is expected to reach USD 64.95 Bn by 2026, growing at a CAGR of 11.2%.
  • According to the International Diabetes Foundation, diabetes affects one in every five persons aged 65 and up throughout the world.
  • However, an important factor restraining the antidiabetics drug market is the decrease in treatment and drug efficacy over time, which can lead to various health issues.
  • In addition, the high cost of medicines is seen as a challenge for the growth of the global antidiabetic drug market.

Uni-Bio Science Group Limited: 2018 Annual Results

Retrieved on: 
Friday, March 29, 2019
Health, Biotechnology, Pharmaceutical, Research, Science, Acarbose, Oligosaccharides, National Music Publishers Association, Tablet computer, Technology

A fully integrated biopharmaceutical company Uni-Bio Science Group Limited (Uni-Bio Science, together with its subsidiaries referred to as the Group, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2018 (the Year), as well as its comparatively figures for the year ended 31 December 2017 (2017).

Key Points: 
  • A fully integrated biopharmaceutical company Uni-Bio Science Group Limited (Uni-Bio Science, together with its subsidiaries referred to as the Group, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2018 (the Year), as well as its comparatively figures for the year ended 31 December 2017 (2017).
  • The Group has completed the BE study of Acarbose tablet and is in the view that BE results are robust.
  • The abbreviated new drug application (ANDA) together with related BE study results were submitted and accepted by the NMPA in December, 2018.
  • Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001.

China's Acarbose Markets, 2013-2017 & 2018-2022

Retrieved on: 
Friday, November 2, 2018
Amino sugars, Acarbose, Oligosaccharides, UNESCO Creative Cities Network, Hangzhou, Bayer, Chemistry, Economy of Germany, Geography of China

The "Investigation Report on China's Acarbose Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Acarbose Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • Acarbose was developed by Bayer in 1975 and first launched in Switzerland in 1986 (trade name: Glucobay).
  • Although Acarbose has been marketed in China for more than 20 years, China's Acarbose market is dominated by Bayer, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. and Sichuan Luye Baoguang Pharmaceutical Co., Ltd. because it is difficult to imitate Acarbose.
  • 2 Sales of Acarbose in China, 2013-2017
    2.3 Sales of Acarbose by Dosage Form in China, 2013-2017
    3 Analysis on Major Acarbose Manufacturers in China, 2013-2017
    3.3 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    3.4 Sichuan Luye Baoguang Pharmaceutical Co., Ltd.
    4 Prices of Acarbose in China, 2017-2018
    4.2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Kaboping)
    4.3 Sichuan Luye Baoguang Pharmaceutical Co., Ltd. (Beixi)
    5 Prospect of China's Acarbose Market, 2018-2022
    Did you know that we also offer Custom Research?